Cardiotoxicity of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma

1. Hall PS et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1(1):72-78. 2. Sternberg CN et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287-1296. 3. Duffaud F et al. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on european organisation for research and treatment of cancer (EORTC). Eur J Cancer. 2015;51(17):2615-2623. 4. Smith SA et al. Dysfunction in the βII Spectrin-Dependent Cytoskeleton Underlies Human Arrhythmia. Circulation. 131(8):2015;695-708. Electrophysiology results at conclusion of treatment Renal cell carcinoma (RCC) is the 6th most common cancer in the U.S., and nearly half of these patients develop cardiovascular (CV) side-effects from the gold-standard therapy—tyrosine kinase inhibitors (TKIs)1-3. Most patients with cancer now die from CV disease rather than from cancer itself. Hence it is imperative to explore the mechanisms by which these life-saving drugs induce heart failure (HF) in order to develop strategies to mitigate these effects and sustain cancer treatment for as long as possible.